All times listed are Pacific Standard Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.
- Home
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster ILocation: Poster Hall
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0229: Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in GoutLocation: Poster Hall
Abstract Poster Presenter: – Kangwon national university hospital
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0230: Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job SyndromeLocation: Poster Hall
Abstract Poster Presenter: – NIH/NIAMS
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0231: Febuxostat Dose Requirement for Achieving Target Serum Urate Levels According to Renal Function: A Retrospective Cohort StudyLocation: Poster Hall
Abstract Poster Presenter: – Asan medical center
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0232: Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USALocation: Poster Hall
Abstract Poster Presenter: – University of Maryland School of Pharmacy
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0233: Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with GoutLocation: Poster Hall
Abstract Poster Presenter: – UCLA
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0234: Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-outLocation: Poster Hall
Abstract Poster Presenter: – Brigham and Women's Hospital
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0235: Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort StudyLocation: Poster Hall
Abstract Poster Presenter: – Brigham and Women's Hospital
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0236: Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial FindingsLocation: Poster Hall
Abstract Poster Presenter: – Horizon Therapeutics plc
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0237: Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network DatabaseLocation: Poster Hall
Abstract Poster Presenter: – Horizon Therapeutics plc
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0238: Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout NomenclatureLocation: Poster Hall
Abstract Poster Presenter: – University of Otago, Christchurch
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0239: Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN DatabaseLocation: Poster Hall
Abstract Poster Presenter: – Horizon Therapeutics
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0240: Gout: A Gateway to Chronic Opioid Use?Location: Poster Hall
Abstract Poster Presenter: – University of Nebraska Medical Center
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0241: Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness TrialLocation: Poster Hall
Abstract Poster Presenter: – University of Nebraska Medical Center
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0242: Venous Thromboembolism in Patients with Gout in the USLocation: Poster Hall
Abstract Poster Presenter: – ICORE
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0243: Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant CenterLocation: Poster Hall
Abstract Poster Presenter: – UT Southwestern Medical Center
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0244: Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in PatientsLocation: Poster Hall
Abstract Poster Presenter: – Arthrosi Therapeutics
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0245: Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with GoutLocation: Poster Hall
Abstract Poster Presenter: – Hospital Universitario Infanta Leonor
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0246: Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 StudiesLocation: Poster Hall
Abstract Poster Presenter: – National Institute of Arthritis and Musculoskeletal and Skin Diseases
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0247: Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United StatesLocation: Poster Hall
Abstract Poster Presenter: – Harvard Pilgrim Health Care Institute
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0248: In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with GoutLocation: Poster Hall
Abstract Poster Presenter: – Department of Rheumatology, Sahlgrenska University hospital
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0249: Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination SurveyLocation: Poster Hall
Abstract Poster Presenter: – Soonchunhyang University Hospital
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0250: Validation of Singe-Shot Computational Polarized Microscopy for Crystal Analysis of Synovial FluidLocation: Poster Hall
Abstract Poster Presenter: – UCLA
-
Sunday, Nov 12th
9:00 AM – 11:00 AM PT0251: Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort StudyLocation: Poster Hall
Abstract Poster Presenter: – Health Management Center, Xiangya Hospital Central South University
-
Sunday, Nov 12th
2:00 PM – 3:00 PM PT12S139: Optimizing Clinical Care in GoutLocation: Room 23A-C
Moderator: – UCLA
Moderator: – New York University Langone Health
-
Sunday, Nov 12th
2:00 PM – 2:15 PM PTMajor Advances in the Management of Gout and Common ComorbiditiesLocation: Room 23A-C
Speaker: – University of Auckland
-
Sunday, Nov 12th
2:15 PM – 2:30 PM PTStrategies for Optimizing Contemporary Gout Care in Patients with Common ComorbiditiesLocation: Room 23A-C
Speaker: – University of Utah
-
Sunday, Nov 12th
2:30 PM – 2:45 PM PTRacial Disparities and Health Inequities in Gout Care in the U.S. and Potential RemediesLocation: Room 23A-C
Speaker: – University of Alabama at Birmingham
-
Sunday, Nov 12th
2:45 PM – 3:00 PM PT -
Sunday, Nov 12th
4:00 PM – 5:30 PM PT12S160: Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (0811–0816)Location: Room 25A-C
Abstract Moderator: – MASSACHUSETTS GENERAL HOSPITAL
Abstract Moderator: – University of Nebraska Medical Center
-
Sunday, Nov 12th
4:00 PM – 4:10 PM PT0811: Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort StudyLocation: Room 25A-C
Presenting Author: – Massachusetts General Hospital
-
Sunday, Nov 12th
4:15 PM – 4:25 PM PT0812: Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization ProcessLocation: Room 25A-C
Presenting Author: – Dr Balmis Alicante General University Hospital-ISABIAL
-
Sunday, Nov 12th
4:30 PM – 4:40 PM PT0813: Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 ParticipantsLocation: Room 25A-C
Presenting Author: – Dr Balmis Alicante General University Hospital-ISABIAL
-
Sunday, Nov 12th
4:45 PM – 4:55 PM PT0814: Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority TrialLocation: Room 25A-C
Presenting Author: – University of Nebraska Medical Center
-
Sunday, Nov 12th
5:00 PM – 5:10 PM PT0815: Intermittent Fasting Reduces Crystal-induced InflammationLocation: Room 25A-C
Presenting Author: – INSERM 1132, BIOSCAR, Lariboisière hospital
-
Sunday, Nov 12th
5:15 PM – 5:25 PM PT0816: Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control StudyLocation: Room 25A-C
Presenting Author: – Taichung Veterans General Hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT(1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster IILocation: Poster Hall
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1100: A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic RuleLocation: Poster Hall
Abstract Poster Presenter: – Columbia University - New York Presbyterian Hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1101: Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic HyperuricemiaLocation: Poster Hall
Abstract Poster Presenter: – Conselleria de Sanitat Universal y Salut pública
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1102: Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)Location: Poster Hall
Abstract Poster Presenter: – Illumination Health
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1103: Evaluation of Outcomes Following Discontinuation of Pegloticase TherapyLocation: Poster Hall
Abstract Poster Presenter: – University of Alabama at Birmingham
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1104: Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical TrialLocation: Poster Hall
Abstract Poster Presenter: – Urica Therapeutics Inc.
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1105: Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout PatientsLocation: Poster Hall
Abstract Poster Presenter: – Jeju National university hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1106: Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel ActivationLocation: Poster Hall
Abstract Poster Presenter: – University Paris Cite
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1107: Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapyLocation: Poster Hall
Abstract Poster Presenter: – Horizon Therapeutics plc
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1108: Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled GoutLocation: Poster Hall
Abstract Poster Presenter: – Horizon Therapeutics plc
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1109: Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant HypothesisLocation: Poster Hall
Abstract Poster Presenter: – Institute of Rheumatology
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1110: Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with GoutLocation: Poster Hall
Abstract Poster Presenter: – Arthrosi therapeutics
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1111: Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysisLocation: Poster Hall
Abstract Poster Presenter: – MetroWest Medical Center
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1112: AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple DosesLocation: Poster Hall
Abstract Poster Presenter: – Arthrosi Therapeutics, Inc.
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1113: Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout PatientsLocation: Poster Hall
Abstract Poster Presenter: – Boston Medical Center Health System
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1114: Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with GoutLocation: Poster Hall
Abstract Poster Presenter: – UNIVERSITY OF BRITISH COLUMBIA
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1115: EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical PracticeLocation: Poster Hall
Abstract Poster Presenter: – Medical University of Vienna
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1116: The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare SystemLocation: Poster Hall
Abstract Poster Presenter: – Massachusetts General Hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1117: Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness AnalysisLocation: Poster Hall
Abstract Poster Presenter: – Massachusetts General Hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1118: The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature ProjectLocation: Poster Hall
Abstract Poster Presenter: – GHICL (Groupement des Hôpitaux de l'Institut Catholique de Lille)
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1119: Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical PracticeLocation: Poster Hall
Abstract Poster Presenter: – IRCCS Galeazzi - Sant'Ambrogio Hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1120: Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout PatientsLocation: Poster Hall
Abstract Poster Presenter: – Massachusetts General Hospital
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1121: Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled TrialsLocation: Poster Hall
Abstract Poster Presenter: – COCHIN HOSPITAL
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1122: The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering TherapyLocation: Poster Hall
Abstract Poster Presenter: – University of Auckland
-
Monday, Nov 13th
9:00 AM – 11:00 AM PT1123: Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016Location: Poster Hall
Abstract Poster Presenter: – Orthopedic Physicians Alaska
-
Monday, Nov 13th
12:00 PM – 1:00 PM PT13M130: New Frontiers in CPPD Care: Optimizing Diagnosis and Clinical OutcomesLocation: Ballroom 20D
Moderator: – Medical College of Wisconsin
Moderator: – Massachusetts General Hospital
-
Monday, Nov 13th
12:00 PM – 12:15 PM PTUltrasound's Role for Differential Diagnosis, Phenotyping, and Management of CPPDLocation: Ballroom 20D
Speaker: – IRCCS Galeazzi - Sant'Ambrogio Hospital
-
Monday, Nov 13th
12:15 PM – 12:30 PM PTCVD Events in CPPD: Risk Assessment and Approaches to Reduce CVD RiskLocation: Ballroom 20D
Speaker: – Brigham and Women's Hospital
-
Monday, Nov 13th
12:30 PM – 12:45 PM PTUpdate in Therapeutic Approaches for Patients with CPPDLocation: Ballroom 20D
Speaker: – Lille Catholic University
-
Monday, Nov 13th
12:45 PM – 1:00 PM PTQ&ALocation: Ballroom 20D
-
Tuesday, Nov 14th
11:45 AM – 11:55 AM PT2428: Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk FactorsLocation: Exhibit Hall A-B
Plenary Presenter: – Massachusetts General Hospital
-
Wednesday, Nov 15th
7:30 AM – 7:45 AM PTL15: AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed TomographyLocation: Room 6A-B
Presenting Author: – Arthrosi Therapeutics
